Drugs / SCD-101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02380079 | Feb 2015 → Nov 2023 | sickle cell disease, sickle cell-beta zero-thalassemia | Invenux, LLC | Unknown | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SCD-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02380079 ↗ |